References

A case of acute renal failure of multiple myeloma due to monoclonal type I cryoglobulinemia with thrombotic microangiopathy.

10.1007/s13730-014-0162-x · 2015 · External reference

Cryoglobulinemia: an update in 2019.

10.1016/j.jbspin.2019.01.016 · 2019 · External reference

The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases.

10.1097/md.0b013e318288925c · 2013 · External reference

Cryoglobulinemia Vasculitis.

10.1016/j.amjmed.2015.02.017 · 2015 · External reference

Renal pathology society/international kidney and monoclonal gammopathy research group consensus on pathologic definitions and terminology of monoclonal gammopathy-associated kidney lesions.

10.1016/j.kint.2025.04.007 · 2025 · External reference

Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: a case report.

10.1186/s12882-020-01818-5 · 2020 · External reference

Proliferative glomerulonephritis due to monoclonal deposition with organized substructures.

10.1053/j.ajkd.2014.08.015 · 2014 · External reference

Infection as a trigger of acute, transient glomerular deposition of clonal immunoglobulins.

10.1080/01913123.2024.2356112 · 2024 · External reference

Kidney diseases associated with Waldenstrom macroglobulinemia.

10.1093/ndt/gfy320 · 2019 · External reference

Types of M protein and clinicopathological profiles in patients with monoclonal gammopathy of renal significance.

10.1007/s40620-020-00817-x · 2021 · External reference

Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases.

10.1016/j.kint.2021.02.038 · 2021 · External reference

Mechanisms of renal damage in plasma cell dyscrasias: an overview.

10.1159/000096761 · 2007 · External reference

An update to the pathogenesis for monoclonal gammopathy of renal significance.

10.1016/j.critrevonc.2020.102926 · 2020 · External reference

Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains.

10.1038/ki.1994.355 · 1994 · External reference

The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis.

10.1016/j.kint.2021.10.019 · 2022 · External reference

Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.

10.1006/jmbi.2001.5092 · 2001 · External reference

Non-light-chain immunoglobulin amyloidosis: time to expand or refine the spectrum to include light+heavy chain amyloidosis?

10.1038/ki.2012.433 · 2013 · External reference

The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.

10.1016/j.kint.2022.03.030 · 2022 · External reference

Natural history and outcome of light chain deposition disease.

10.1182/blood-2015-07-658872 · 2015 · External reference

Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits.

10.1016/j.mayocp.2015.01.024 · 2015 · External reference

A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

10.1016/j.kint.2018.02.020 · 2018 · External reference

Bridging the divide: an onco-nephrologic approach to the monoclonal gammopathies of renal significance.

10.2215/cjn.03160316 · 2016 · External reference

Renal-limited cryoglobulinemic vasculitis: two case reports.

10.2169/internalmedicine.0131-17 · 2018 · External reference

Lammerts.

10.1080/19420862.2015.1007813 · 2015 · External reference

CD38 antibodies in multiple myeloma: back to the future.

10.1182/blood-2017-06-740944 · 2018 · External reference

Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma.

10.1158/1078-0432.ccr-16-3192 · 2017 · External reference

Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma.

10.1093/oncolo/oyac067 · 2022 · External reference

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

10.1182/blood.2019004460 · 2020 · External reference

Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis.

10.1080/07853890.2024.2442075 · 2025 · External reference

Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits.

10.1681/asn.2020101541 · 2021 · External reference